The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30503
Abstract: Oncogenic mutations of BRAF lead to constitutive ERK activity that supports melanoma cell growth and survival. While Ca2+ signaling is a well‐known regulator of tumor progression, the crosstalk between Ca2+ signaling and the Ras‐BRAF‐MEK‐ERK pathway… read more here.
Keywords: melanoma; braf mutant; mutant melanoma; pmca4b ... See more keywords
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Colorectal Disease"
DOI: 10.1007/s00384-020-03589-9
Abstract: Purpose BRAF mutations represent the main negative prognostic factor for metastatic colorectal cancer and a supposed negative predictive factor of response to standard chemotherapy. We have explored survival difference in right-sided colon cancer (RCC) patients… read more here.
Keywords: braf mutant; right sided; difference; braf ... See more keywords
Curcumin Chemoprevention Reduces the Incidence of Braf Mutant Colorectal Cancer in a Preclinical Study
Sign Up to like & getrecommendations! Published in 2021 at "Digestive Diseases and Sciences"
DOI: 10.1007/s10620-020-06752-y
Abstract: Colorectal cancer is a leading cause of cancer-related death worldwide and approximately 20% of cases can be attributed to a mutation in the BRAF oncogene. Curcumin is a promising chemopreventive agent with various anti-cancer benefits.… read more here.
Keywords: braf mutant; colorectal cancer; study; cancer ... See more keywords
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check‐Point Inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.04.024
Abstract: Introduction: The efficacy of immune checkpoint inhibitors (ICPi) in BRAF mutant NSCLC is unknown. Methods: Multi‐institutional retrospective chart review identified 39 patients with BRAF mutant NSCLC. The patients were divided into two groups: V600E (group… read more here.
Keywords: braf mutant; response; instability status; expression ... See more keywords
VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Translational Oncology"
DOI: 10.1016/j.tranon.2019.10.007
Abstract: Vemurafenib, an inhibitor of mutant BRAF activity, is a promising anticancer agent for patients with BRAF-mutant metastatic melanoma. However, it is less effective in BRAF-mutant thyroid cancer, and the reason for this discrepancy is not… read more here.
Keywords: braf mutant; vcam; thyroid; thyroid cancer ... See more keywords
Clinical trial results show promise of targeting autophagy BRAF mutant melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Autophagy"
DOI: 10.1080/15548627.2022.2038899
Abstract: ABSTRACT Macroautophagy/autophagy is a resistance mechanism to targeted therapy in BRAF mutant cancers. Preclinical evidence and clinical trial data demonstrate that hydroxychloroquine (HCQ) is an effective autophagy inhibitor at clinically achievable concentrations. Here we highlight… read more here.
Keywords: melanoma; trial; braf mutant; mutant melanoma ... See more keywords
HGG-34. Upfront Molecular Targeted Therapy for the Treatment of BRAF-mutant Pediatric High-Grade Glioma
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noac079.249
Abstract: BACKGROUND: The prognosis for pediatric high-grade glioma (pHGG) is poor despite aggressive multi-modal therapy. Objective responses to targeted therapy with BRAF inhibitors have been reported in some patients with recurrent BRAF-mutant pHGG but are rarely… read more here.
Keywords: braf mutant; targeted therapy; high grade; therapy ... See more keywords
RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
Sign Up to like & getrecommendations! Published in 2023 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001500
Abstract: Reactive oxygen species (ROS) levels are elevated after acquisition of resistance to v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors including dabrafenib and MEK inhibitors such as trametinib in BRAF-mutant melanoma. To circumvent toxicity… read more here.
Keywords: tdr; ridr 103; braf; inhibitor ... See more keywords
Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004095
Abstract: Background Patients with BRAF-mutant and wild-type melanoma have different response rates to immune checkpoint blockade therapy. However, the reasons for this remain unknown. To address this issue, we investigated the precise immune composition resulting from… read more here.
Keywords: braf; melanoma; mutant melanoma; treatment naive ... See more keywords
Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-1795
Abstract: Mutations in BRAF outside of the 600 codons (BRAF non- V600) occur across cancer types, including in 3% to 5% of melanomas. The optimal treatment strategies are not clear but based on preclinical studies could… read more here.
Keywords: braf mutant; class matters; sensitivity braf; mutant melanoma ... See more keywords
BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-17-1124
Abstract: Metastatic melanoma is characterized by complex genomic alterations, including a high rate of mutations in driver genes and widespread deletions and amplifications encompassing various chromosome regions. Among them, chromosome 7 is frequently gained in BRAF-mutant… read more here.
Keywords: melanoma; braf mutant; copy number; mapk inhibitors ... See more keywords